Rheumatology Advisor

FDA to Review Brepocitinib for Treatment of Dermatomyositis

The FDA accepted a New Drug Application with Priority Review for brepocitinib, an oral TYK2/JAK1 inhibitor, for the treatment of dermatomyositis.
Healio

VIDEO: Early, continuous pegcetacoplan treatment improves GA outcomes

In this video from the Macula Society meeting, Theodore Leng, MD, FACS, discusses 5-year data on pegcetacoplan, from Apellis, for geographic atrophy.“This presentation really supported the notion that ...
Healthline

FDA Doesn’t Endorse Leucovorin for Autism, OKs It for Rare Brain Disorder

The FDA declined to endorse leucovorin as a treatment for autism, but approved the drug to treat cerebral folate deficiency, ...

No Broad Autism Approval for Leucovorin, Despite FDA Commissioner’s Prior Suggestions

The Food and Drug Administration on March 10 changed the approval for a version of the prescription drug leucovorin to include people with a very rare genetic condition. FDA Commissioner Dr. Marty ...
Healio

FDA approves Cosentyx for teens 12 and older with hidradenitis suppurativa

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...